CTS: 3 Key Takeaways for Long-Term Investors

On its third-quarter 2026 earnings call, held on Oct. 27, 2026, CTS (NYSE:CTS) raised its full-year sales guidance to between $580 million and $590 million. The component manufacturer is shifting its revenue base toward higher-margin medical and industrial markets while light vehicle production slows.

Three takeaways from management show how this business model transition is progressing.

Management completed the acquisition of Millar for $50 million in cash, adding $30 million in annual medical sensor revenue. The deal accelerates the company's strategic push into healthcare applications, where medical segment sales grew 21% year over year to $27 million.

Continue reading